Summary
- Profile Type
- Technology offer
- POD Reference
- TODE20250212013
- Term of Validity
- 12 February 2025 - 12 February 2026
- Company's Country
- Germany
- Type of partnership
- Commercial agreement with technical assistance
- Targeted Countries
- All countries
Contact the EEN partner nearest to you for more information.
Find my local partner
General information
- Short Summary
- he innovation presented here from a German university improves the early diagnosis of lupus nephritis (kidney inflammation). It improves patient care because the diagnosis can be made through a non-invasive procedure in the patient. The university is offering a license agreement.
- Full Description
-
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with a prevalence of 20-50 per 100,000 people in European cohorts. Up to half of patients develop lupus nephritis (LN), and 10-20% of these patients develop end-stage renal failure requiring dialysis. Although anti-dsDNA antibodies are well established for the diagnosis and monitoring of SLE, the current reliance on renal biopsies to confirm LN is a sign of the urgent need for a reliable, non-invasive diagnostic method.
Current approaches do not provide a validated biomarker to detect renal involvement in SLE.
To address this limitation, a recent analysis by researchers at a German university of an SLE cohort identified a specifically guanidylated form of the protein YB-1 (YB-1-2G) that is detectable at particularly high levels in the serum of patients with active SLE and LN. Corresponding autoantibodies (anti-YB-1-2G) were also detected.
Based on these results, two enzyme-linked immunosorbent assay (ELISA)-based approaches are currently being developed:
1. an ELISA to detect YB-1-2G in serum, initially using a polyclonal antibody, with a planned transition to a monoclonal antibody for higher specificity.
2. a second ELISA for the detection of circulating autoantibodies against YB-1-2G.
These innovations are expected to significantly improve patient care by providing a non-invasive diagnosis of LN.
The university offers a license agreement to companies in the diagnostic sector. - Advantages and Innovations
-
The main advantages are:
- Non-Invasive detection
- Diagnosis via established method possible
- Lifesaving diagnosis: Earlier detection of Lupus Nephritis - Stage of Development
- Under development
- Sustainable Development Goals
- Goal 3: Good Health and Well-being
- IPR status
- IPR applied but not yet granted
- IPR notes
- A patent application has been filed with the European and United States Patent Offices.
Partner Sought
- Expected Role of a Partner
- The university offers a license agreement to companies in the diagnostic sector. An ELISA with a polyclonal antibody is currently being developed, but the switch to a monoclonal antibody would have to be made with a company.
- Type and Size of Partner
- SME <=10
- Big company
- SME 50 - 249
- Other
- SME 11-49
- Type of partnership
- Commercial agreement with technical assistance
Dissemination
- Technology keywords
- 06001005 - Diagnostics, Diagnosis
- Market keywords
- 05001007 - Other diagnostic
- Sector Groups Involved
- Health
- Targeted countries
- All countries
